- Home
- OPOF vs AVR Comparison
OPOF vs AVR Comparison
Compare OPOF & AVR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPOF
- AVR
- Stock Information
- Founded
- OPOF 1922
- AVR 1999
- Country
- OPOF United States
- AVR Australia
- Employees
- OPOF N/A
- AVR N/A
- Industry
- OPOF Major Banks
- AVR
- Sector
- OPOF Finance
- AVR
- Exchange
- OPOF Nasdaq
- AVR NYSE
- Market Cap
- OPOF 207.2M
- AVR 241.5M
- IPO Year
- OPOF N/A
- AVR 2024
- Fundamental
- Price
- OPOF $39.55
- AVR $4.24
- Analyst Decision
- OPOF
- AVR Strong Buy
- Analyst Count
- OPOF 0
- AVR 4
- Target Price
- OPOF N/A
- AVR $16.50
- AVG Volume (30 Days)
- OPOF 9.0K
- AVR 148.4K
- Earning Date
- OPOF 07-24-2025
- AVR 05-13-2025
- Dividend Yield
- OPOF 1.42%
- AVR N/A
- EPS Growth
- OPOF 55.28
- AVR N/A
- EPS
- OPOF 1.96
- AVR N/A
- Revenue
- OPOF $61,370,000.00
- AVR $2,493,000.00
- Revenue This Year
- OPOF N/A
- AVR $29.52
- Revenue Next Year
- OPOF N/A
- AVR $204.83
- P/E Ratio
- OPOF $20.19
- AVR N/A
- Revenue Growth
- OPOF 5.28
- AVR N/A
- 52 Week Low
- OPOF $13.70
- AVR $2.34
- 52 Week High
- OPOF $40.88
- AVR $8.79
- Technical
- Relative Strength Index (RSI)
- OPOF 56.41
- AVR N/A
- Support Level
- OPOF $38.83
- AVR N/A
- Resistance Level
- OPOF $40.30
- AVR N/A
- Average True Range (ATR)
- OPOF 0.68
- AVR 0.00
- MACD
- OPOF -0.24
- AVR 0.00
- Stochastic Oscillator
- OPOF 35.12
- AVR 0.00
About OPOF Old Point Financial Corporation
Old Point Financial Corp functions in the financial services domain in the United States. As the holding company of The Bank and Trust, it is a nationally chartered trust and wealth management service, provider. Its suite of services includes commercial banking solutions such as loan, deposit and cash management, which are rendered through a chain of branches throughout the country. It operates through segments such as Bank, Wealth and Company.
About AVR ANTERIS TECHNOLOGIES GLOBAL CORP
Anteris Technologies Global Corp. is a structural heart company committed to discovering, developing and commercializing medical devices designed to improve the quality of life for patients with aortic stenosis. Its product, the DurAVR THV system, represents a product opportunity in a new THV class of single-piece heart valves, for the treatment of aortic stenosis. Its DurAVR THV system consists of a single-piece, biomimetic valve made with its proprietary ADAPT tissue-enhancing technology and deployed with its ComASUR balloon-expandable delivery system. ADAPT is its proprietary anti-calcification tissue shaping technology that is designed to reengineer xenograft tissue into a pure, single-piece collagen bioscaffold.